Cardiff Oncology Inc. (NASDAQ:CRDF) currently has a daily average trading volume of 545.63K but it saw 396387 shares traded on Wednesday. With a market cap of 60.72M USD, stock’s current market price of $1.38 came rising about 6.98 while comparing to the previous closing price of $1.29. In past 52 weeks, the stock remained buoying in the range of price level as high as $7.32 and as low as $1.13. In the recent trading on the day, stock has struck highest price mark of $1.46 while lowest mark touched by it was $1.31.
Taking a look at 20-day trading activity of Cardiff Oncology Inc. (CRDF) gives us an average price of $1.3905, while its current price level is -81.15% below from 52-week high level whereas it is 22.12% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $1.5004 while that of 200 days or SMA-200 reads an average of $2.0416. A closer look into the stock’s movement over the week reveals that its volatility is standing at 8.74% during that period while stretching the period over a month that decreases to 6.99%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 46.86 which implies that the stock is in neutral territory.
Cardiff Oncology Inc. (CRDF)’s stock is currently under the radar of 5 analysts who are in consensus at a 12-month price target range of between $5.00 and $14.00 for company’s shares. The average price target assigned by the average number of analysts to a stock is a way to gauge worth of any stock in next 52 weeks. And in assigning price target to a stock, some analysts adopt a bearish approach by advocating lower-than-average price target which in this case is $5.00 while some adopt bullish approach by assigning higher-than-average price target which reads the price to top $14.00. Average price target assigned by them is $8.00 which highlights an upside potential of 82.75% for the stock over that period. And to attain the median price target of $5.00 assigned by those analysts, stock has to add about 72.4% of value to its current levels.
Data by FactSet Research shows that 5 analysts have issued their ratings for the stock. 0 of them are in opinions that stock is a Sell, while 1 are advising it as an Overweight. 4 analysts suggested the investors to Buy the stock while 0 advised them to Hold. Recommendations by all of those brokerages imply a consensus rating of Buy for the stock and that issued by Wall Street to investors is Strong Buy.
Maxim Group issued its recommendations for the stock as it resumed the price target for the stock in the range of between $30 and $20.
Over the week, CRDF’s stock price is moving 6.15% up while it is -9.21% when we observe its performance for the past one month. Year-to-date it is -77.04% down and over the past year, the stock is showing a downside performance of -74.35%.
The latest quarterly earnings report issued by the company was for quarter ended 6/29/2022, when its quarterly earnings per share (EPS) of -$0.24 beat the consensus estimate of -$0.25 for the same. For CRDF, analysts are forecasting an EPS-growth rate of -39.70% for current year and estimate for EPS growth in next year is -25.50%. In next quarter, company is expected to be making quarterly sales of $70k as analysts are expecting the sales for current fiscal year at $310k and seeing the company making $140k in sales next year. Moreover, analysts are in estimates of $70k for current-quarter revenue.
Currently, Cardiff Oncology Inc.’s total number of outstanding shares is 43.33M with 7.56% of that held by the insiders while 21.38% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -20.60% and return on equity (ROE) at -31.30%. Stock’s beta reads 1.53. Stock has a price to book (P/B) ratio of 0.53 while price to sale or P/S ratio amounts to 151.80. Its return on asset (ROA) is -29.00% on average.
In the most recent quarter, Stichting Pensioenfonds ABP came rising its stake by 8.74% in the company and now holds 0.38 million or 0.87% of the company’s stake having worth of about 0.62 million.